EGFR and neoplasm: In line with this, suppression of viability and tumour growth was more consistent when ARS-1620 was combined with GDC0941 (pan-PI3K inhibitor), compared to afatanib (EGFR/ErbB inhibitor), in different ARS-1620 monotherapy-resistant models.